×

Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG). Gastric Cancer. 2018 Feb 9. doi: 10.1007/s10120-018-0806-1. [Epub ahead of print] - Co-1st author

Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. Cancer Res Treat. 2018 Feb 5. doi: 10.4143/crt.2018.028. [Epub ahead of print]-Co-1st author

Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. Gastric Cancer. 2018 Jan 25. doi: 10.1007/s10120-018-0794-1. [Epub ahead of print]

Kim JH, Shin SJ, Heo SJ, Choe EA, Kim CG, Jung M, Keum KC, Yoon JS, Lee SC, Shin SJ. Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma. Cancer Res Treat. 2017 Dec 28. doi: 10.4143/crt.2017.534. [Epub ahead of print]

Ji Soo Park, Jong-Chan Youn, Chi Young Shim, Geu-Ru Hong, Choong-Kun Lee, Jee Hyung Kim, Hyung Soon Park, Su Jin Heo, Seung Hoon Beom, Hyo Song Kim, Sun Young Rha, Hyun Cheol Chung, Seok-Min Kang, and Minkyu Jung. Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. Oncotarget. 2017; 8:61837-61845-Corresponding author

Kim CG, Ahn JB, Shin SJ, Beom SH, Heo SJ, Park HS, Kim JH, Choe EA, Koom WS, Hur H, Min BS, Kim NK, Kim H, Kim C, Jung I, Jung M. Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. BMC Cancer. 2017 Sep 2;17(1):615-Corresponding author

Park JS, Lee N, Beom SH, Kim HS, Lee CK, Rha SY, Chung HC, Yun M, Cho A, Jung M. The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. Gastric Cancer. 2017 Jun 22. doi: 10.1007/s10120-017-0739-0. [Epub ahead of print] -Corresponding author

Kim HS, Lee H, Shin SJ, Beom SH, Jung M, Bae S, Lee EY, Park KH, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Park JC, Shin SK, Lee SK, Lee YC, Koom WS7, Lim JS, Chung HC, Noh SH, Rha SY, Kim H, Paik S. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. Oncotarget. 2017 Jun 13;8(24):38389-38398.

Lee CK, Kim SS, Park S, Kim C, Heo SJ, Lim JS, Kim H, Kim HS, Rha SY, Chung HC, Park S, Jung M. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. Oncotarget. 2017 May 9;8(19):31169-31179-Corresponding author

HS Kim, M Jung, HN Kang, H Kim, C-W Park, S-M Kim, SJ Shin, SH Kim, SG Kim, EK Kim, MR Yun, Z Zheng, KY Chung, J Greenbowe, SM Ali, T-M Kim and BC Cho. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. Oncogene. 2017 Jan 16. Epub. ?Co-1st author

Kim CG, Ahn JB, Jung M, Beom SH, Heo SJ, Kim JH, Kim YJ, Kim NK, Min BS, Koom WS, Kim H, Roh YH, Ma BG, Shin SJ. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer. Ann Surg Oncol. 2017 Jan;24(1):227-235.

Yoon HI, Koom WS, Kim TH, Ahn JB, Jung M, Kim TI, Kim H, Shin SJ, Kim NK. Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors. PLoS One. 2016 Aug 18;11(8):e0161475.

Kim HS, Shin SJ, Beom SH, Jung M, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Noh SH, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Rha SY, Kim H. Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. Oncotarget. 2016 Jul 12;7(28):44608-44620.

Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, Min BS, Kim H, Koom WS, Shin SJ. Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. Br J Cancer. 2016 Jun 28;115(1):25-33

Jung M, Lee J, Kim TM, Lee DH, Kang JH, Oh SY, Lee SJ, Shin SJ. Ipilimumab Real-world Efficacy and Safety in Korean melanoma Patients from the Korean Named-Patient Program Cohort. Cancer Res Treat. 2017 Jan;49(1):44-53. - Co-1st author

Lim SM, Cho BC, Kim SW, Kang SY, Heo DS, Kim HT, Lee DH, Kim DW, Jung M, Choi JH, Shim HS, Choi JR, Kim JH. A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). Lung Cancer. 2016 Mar;93:1-8.

Lim SM, Kim H, Kang B, Kim HS, Rha SY, Noh SH, Hyung WJ, Cheong JH, Kim HI, Chung HC, Yun M, Cho A, Jung M. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. Ann Nucl Med. 2016 May;30(4):279-86. -Corresponding author

Kim KH, Shin SJ, Cho MS, Ahn JB, Jung M, Kim TI, Park YS, Kim H, Kim NK, Koom WS. A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis. Radiother Oncol. 2015 Dec 16. pii: S0167-8140(15)00649-0. doi: 10.1016/j.radonc.2015.11.029. [Epub ahead of print]

Jung M, Shin SJ, Koom WS, Jung I, Keum KC, Hur H, Min BS, Baik SH, Kim NK, Kim H, Lim JS, Hong SP, Kim TI, Roh JK, Park YS, Ahn JB. A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer. Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1015-22.

Park HS, Jung M, Shin SJ, Heo SJ, Kim CG, Lee MG, Beom SH, Lee CY, Lee JG, Kim DJ, Ahn JB. Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer. Ann Surg Oncol. 2015 Oct 29. [Epub ahead of print] -Corresponding author

Lee CK, Jung M, Choi HJ, Kim HR, Kim HS, Roh MR, Ahn JB, Chung HC, Heo SJ, Rha SY, Shin SJ. Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients who Failed First-line Therapy Containing Darcabazine. Cancer Res Treat. 2015 Feb 16. doi: 10.4143/crt.2014.261. [Epub ahead of print]

Heo SJ, Lee CK, Hahn KY, Kim G, Hur H, Choi SH, Han KS, Cho A, Jung M. A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas. Cancer Res Treat. 2015 Feb 17. doi: 10.4143/crt.2014.299. [Epub ahead of print] -Corresponding author

Lee CK, Jung M, Jung I, Heo SJ, Jeong YH, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, Kim HS, Rha SY, Chung HC. Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. Ann Surg. 2015 Jan 8. [Epub ahead of print]-Corresponding author

Lim SM, Jung M, Shin SJ, Baek SJ, Hur H, Min BS, Baik SH, Kim NK, Ahn JB. Clinical Implications from a Single-Center Study of Colorectal Adenocarcinoma in Transplant Recipients. Oncology. 2014 Dec 5;88(4):195-200. [Epub ahead of print]

Park JS, Rha SY, Chung HC, Jung M, Kim KH, Jun HJ, Kim H, An JY, Kim HI, Cheong JH, Hyung WJ, Noh SH, Kim HS. Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer. Oncology. 2014 Nov 13;88(3):147-156. [Epub ahead of print]

Zhang X, Park JS, Park KH, Kim KH, Jung M, Chung HC, Rha SY, Kim HS.PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer. Oncology. 2015;88(2):76-85

Park HS, Jung M, Kim HS, Kim HI, An JY, Cheong JH, Hyung WJ, Noh SH, Kim YI, Chung HC, Rha SY. Proper timing of adjuvant chemotherapy affects survival in patients with stage 2 and 3 gastric cancer. Ann Surg Oncol. 2015 Jan;22(1):224-31- Co-1st author

Ahn HK, Jung M, Sym SJ, Shin DB, Kang SM, Kyung SY, Park JW, Jeong SH, Cho EK. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2014 Jun 7.

Ahn HK, Jung M, Ha SY, Lee JI, Park I, Kim YS, Hong J, Sym SJ, Park J, Shin DB, Lee JH, Cho EK. Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer. Tumour Biol. 2014 Jun;35(6):5735-40- Co-1st author

Yi JH, Kim H, Jung M, Shin SJ, Choi JS, Choi GH, Baik SH, Min BS, Kim NK, Ahn JB. Prognostic factors for disease-free survival after preoperative chemotherapy followed by curative resection in patients with colorectal cancer harboring hepatic metastasis: a single-institute, retrospective analysis in Asia. Oncology. 2013;85(5):283-9

Jung M, Lee CH, Park HS, Lee JH, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Cho BC. Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. Yonsei Med J. 2013 Jul;54(4):854-64

Jung M, Choi EH, Nam CM, Rha SY, Jeung HC, Lee SH, Yang WI, Roh JK, Chung HC. Application of the adjuvant! Online model to korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool. Ann Surg Oncol. 2013 Aug;20(8):2615-24.

Jung M, Cho BC, Lee CH, Park HS, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Lee JH. EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Med J. 2012 Nov 1;53(6):1128-35

Jung M, Kim GW, Jung I, Ahn JB, Roh JK, Rha SY, Chung HC, Kim NK, Kim TI, Shin SJ. Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience. BMC Cancer. 2012 Oct 12;12:471

Jung M, Koo JS, Moon YW, Park BW, Kim SI, Park S, Lee SH, Hong S, Rha SY, Chung HC, Kim JH, Sohn J. Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy. PLoS One. 2012;7(9):e45127. doi: 10.1371/journal.pone.0045127. Epub 2012 Sep 20

Sym SJ, Hong J, Jung M, Park J, Cho EK, Lee WK, Chung M, Kim HS, Lee JH, Shin DB. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 2012 Aug;70(2):277-84. Epub 2012 Jun 30.

Noh S, Jung JJ, Jung M, Kim KH, Lee HY, Wang B, Cho J, Kim TS, Jeung HC, Rha SY. Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. Oncol Lett. 2012 Mar;3(3):699-703. Epub 2012 Jan 3.

Noh S, Jung JJ, Jung M, Kim TS, Park CH, Lim SJ, Jeung HC, Cheol H, Chung HC, Rha SY. MMP-2 as a Putative Biomarker for Carcinomatosis in Gastric Cancer. Hepatogastroenterology. 2011 Oct 12;58(112). doi: 10.5754/hge11209. [Epub ahead of print]

Hong J, Park S, Park J, Kim HS, Kim KH, Ahn JY, Rim MY, Jung M, Sym SJ, Cho EK, Shin DB, Lee JH. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leuk Lymphoma. 2011 Oct;52(10):1904-12. Epub 2011 Jun 30.

Jung M, Kim SH, Lee YJ, Hong S, Kang YA, Kim SK, Chang J, Rha SY, Kim JH, Kim DJ, Cho BC. Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Exp Ther Med. 2011 Jul;2(4):685-693

Hong J, Jung M, Kim YJ, Sym SJ, Kyung SY, Park J, Lee SP, Park JW, Cho EK, Jeong SH, Shin DB, Lee JH. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemother Pharmacol. 2011 Jun 21. [Epub ahead of print]

Hong S, Shin SJ, Jung M, Jeong J, Lee YJ, Shin KH, Roh JK, Rha SY. Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity. Oncology. 2011 Jun 14;80(1-2):107-117. [Epub ahead of print]

Shin SJ, Jung M, Jeung HC, Kim HR, Rha SY, Roh JK, Chung HC, Ahn JB. A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy. Invest New Drugs. 2011 May 13. [Epub ahead of print]

Hong S, Cho BC, Choi HJ, Jung M, Lee SH, Park KS, Kim SK, Kim JH. Prognostic Factors in Small Cell Lung Cancer: A New Prognostic Index in Korean Patients.Oncology. 2011 Mar 16;79(3-4):293-300. [Epub ahead of print]

Jung M, Ahn JB, Chang JH, Suh CO, Hong S, Roh JK, Shin SJ, Rha SY. Brain metastases from colorectal carcinoma: prognostic factors and outcome. J Neurooncol. 2011 Jan;101(1):49-55. Epub 2010 May 14. J Neurooncol. 2010 May 14.

Jung M, Shin HJ, Rha SY, Jeung HC, Hong S, Moon YW, Kim HS, Oh KJ, Yang WI, Roh JK, Chung HC. The clinical outcome of chemotherapy induced amenorrhea in premenopausal young breast cancer patients with long term follow up. Ann Surg Oncol. 2010 Dec;17(12):3259-3268. Epub 2010 Jun 19.

Jung M, Jeung HC, Lee SS, Park JY, Hong S, Lee SH, Noh SH, Chung HC, Rha SY. The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites. J Cancer Res Clin Oncol. 2010 Apr;136(4):517-26. Epub 2009 Sep 23.

Jung JJ, Noh S, Jeung HC, Jung M, Kim TS, Noh SH, Roh JK, Chung HC, Rha SY. Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression. Cancer Sci. 2010 Oct;101(10):2200-6. doi: 10.1111/j.1349-7006.2010.01666.x. Epub 2010 Aug 22

Jeong J, Cho BC, Sohn JH, Choi HJ, Kim SH, Lee YJ, Jung MK, Shin SJ, Park MS, Kim SK, Chang J, Kim JH. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial. Lung Cancer. 2010 Oct;70(1):77-81. Epub 2010 Mar 16.
Son JW, Kim JS, Lee JM, Hong SJ, Jung MK, Kim DH, Kim JS, Choi D, Jang Y. Percutaneous cardiopulmonary support in refractory no-reflow with cardiogenic shock after coronary stenting in acute myocardial infarction. Yonsei Med J. 2010 Jul;51(4):599-601.

Moon YW, Sohn JH, Kim YT, Chang H, Jeong JH, Lee YJ, Chang J, Kim SK, Jung M, Hong S, Choi SH, Kim JH. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided versus empirical chemotherapy in unresectable non-small cell lung cancer. Anticancer Res. 2009 Oct;29(10):4243-9.

Ahn JR, Jung M, Kim C, Hong MH, Chon HJ, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, Noh SH, Rha SY. Prognosis of pN3 Stage Gastric Cancer. Cancer Res Treat. 2009 Jun;41(2):73-9. Epub 2009 Jun 30

Kim DH, Cheon JH, Moon CM, Park JJ, Han SY, Kim ES, Chung MJ, Lee JH, Jung MK, Lee SH, Son JW, Kim TI, Kim WH. Clinical efficacy of nonsurgical treatment of Crohn's disease-related intraabdominal abscess. Korean J Gastroenterol. 2009 Jan;53(1):29-35.

Jung MK, Hong SJ, Lee SH, Hong SJ, Son JW, Kang W, Lee YW, Hong CS, Lee JK, Park JW. Development and Validation of a Korean Allergic Rhinitis-specific Quality of Life Questionnaire (KARQLQ). Korean J Asthma Allergy Clin Immunol 2008;28:113-120

Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer
ONCOLOGIST 24/11 :e1108-e1114,2019

Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
EUROPEAN JOURNAL OF CANCER 112/ :20-28,2019

Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer
GASTRIC CANCER 22/6 :1,153-1,163,2019

Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
Journal for ImmunoTherapy of Cancer 7/1 :e268-,2019

Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
CANCER RESEARCH AND TREATMENT 51/2 :819-831,2019

Screening for Lung Cancer Using Low-dose Chest Computed Tomography in Korean Long-term Colorectal Cancer Survivors
Journal of Cancer Prevention 24/1 :48-53,2019

Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer
RADIOTHERAPY AND ONCOLOGY 140/ :143-149,2019

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
CANCER RESEARCH AND TREATMENT 51/1 :1-11,2019

Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy
BMC CANCER 18/1 :1116-1127,2018

Casein Kinase 2 Inhibitor, CX-4945, as a Potential Targeted Anticancer Agent in Gastric Cancer.
ANTICANCER RESEARCH 38/11 :6,171-6,180,2018

Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.
CLINICAL CANCER RESEARCH 24/21 :5,272-5,281,2018

Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma
CANCER RESEARCH AND TREATMENT 50/4 :1238-1251,2018

Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
GASTRIC CANCER 21/5 :819-830,2018

Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial.
ANNALS OF SURGICAL ONCOLOGY 25/11 :3,222-3,230,2018

A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy
AAPS JOURNAL 20/4 :72-87,2018

Predictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative Resection
CLINICAL COLORECTAL CANCER 17/3 :513-518,2018

The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status
GASTRIC CANCER 21/2 :213-224,2018

Correlation between KRAS mutation and 18F-FDG uptake in stage IV colorectal cancer
ABDOMINAL RADIOLOGY 42/6 :1,621-1,626,2017

Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
ONCOGENE 36/23 :3,334-3,345,2017

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
ONCOTARGET 8/37 :61,837-61,845,2017

Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery
BMC CANCER 17/615 :615-625,2017

Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
ONCOTARGET 8/24 :38,389-38,398,2017

Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer
ANNALS OF SURGICAL ONCOLOGY 24/1 :227-235,2017

Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
ONCOTARGET 8/19 :31,169-31,179,2017

Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort
CANCER RESEARCH AND TREATMENT 49/1 :44-53,2017

Benefit of Adjuvant Chemotherapy After Curative Resection of Lung Metastasis in Colorectal Cancer
ANNALS OF SURGICAL ONCOLOGY 23/ :928-935,2016

Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers
BRITISH JOURNAL OF CANCER 115/1 :25-33,2016

A New Practical Desensitization Protocol for Oxaliplatin-Induced Immediate Hypersensitivity Reactions: A Necessary and Useful Approach
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY 26/3 :168-176,2016

Upfront Systemic Chemotherapy and Short-Course Radiotherapy with Delayed Surgery for Locally Advanced Rectal Cancer with Distant Metastases: Outcomes, Compliance, and Favorable Prognostic Factors
PLOS ONE 11/8 :e0161475-,2016

Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: Implications for individualized therapy
ONCOTARGET 7/28 :44608-44620,2016

Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma
ANNALS OF NUCLEAR MEDICINE 30/4 :279-286,2016

수술 후 항암화학요법을 받는 대장암 환자들의 운동 인식에 대한 현상학적 연구
한국체육학회지 55/1 :687-700,2016

A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis
RADIOTHERAPY AND ONCOLOGY 118/2 :369-374,2016

A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806)
LUNG CANCER 93/0 :1-8,2016

Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy
ANNALS OF SURGERY 263/1 :96-102,2016

A Case of von Hippel?Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas
CANCER RESEARCH AND TREATMENT 48/1 :409-414,2016

A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 93/5 :1015-1022,2015

Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine
CANCER RESEARCH AND TREATMENT 74/4 :781-789,2015

Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer
ONCOLOGY 88/3 :147-156,2015

Clinical Implications from a Single-Center Study of Colorectal Adenocarcinoma in Transplant Recipients
ONCOLOGY 88/4 :195-200,2015

Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer
ANNALS OF SURGICAL ONCOLOGY 22/1 :224-231,2015

PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer
ONCOLOGY 88/2 :76-85,2015

Clinical significance of Ki-67 and p53 expression in curatively resected non-small cell lung cancer
TUMOR BIOLOGY 35/6 :5735-5740,2014

A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer
CANCER CHEMOTHERAPY AND PHARMACOLOGY 74/2 :277-282,2014

Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis.
JOURNAL OF SURGICAL ONCOLOGY 110/2 :214-221,2014

Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
YONSEI MEDICAL JOURNAL 54/4 :854-864,2013

Application of the adjuvant! Online model to korean breast cancer patients: an assessment of prognostic accuracy and development of an alternative prognostic tool.
ANNALS OF SURGICAL ONCOLOGY 20/8 :2615-2624,2013

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
YONSEI MEDICAL JOURNAL 53/6 :1128-1135,2012

Application of the Western-based adjuvant online model to Korean colon cancer patients; a single institution experience
BMC CANCER 12/1 :471-471,2012

A phase i pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
INVESTIGATIONAL NEW DRUGS 30/4 :1501-1510,2012

Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy.
PLOS ONE 7/9 :e45127-e45127,2012

Body fluid MMP-2 as a putative biomarker in metastatic breast cancer
ONCOLOGY LETTERS 3/3 :699-703,2012

MMP-2 as a Putative Biomarker for Carcinomatosis in Gastric Cancer
HEPATO-GASTROENTEROLOGY 58/112 :2015-2019,2011

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib
EXPERIMENTAL AND THERAPEUTIC MEDICINE 2/ :685-693,2011

Comparison of Long-Term Outcome between Doublet and Triplet Neoadjuvant Chemotherapy in Non-Metastatic Osteosarcoma of the Extremity
ONCOLOGY 80/1-2 :107-117,2011

Brain metastases from colorectal carcinoma: prognostic factors and outcome
JOURNAL OF NEURO-ONCOLOGY 101/ :49-55,2011

Prognostic Factors in Small Cell Lung Cancer: A New Prognostic Index in Korean Patients
Oncology 79/3-4 :293-300,2010

Percutaneous Cardiopulmonary Support in Refractory No-Reflow with Cardiogenic Shock after Coronary Stenting in Acute Myocardial Infarction
YONSEI MEDICAL JOURNAL 51/4 :599-601,2010

The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up
Annals of Surgical Oncology 17/12 :3259-3268,2010

Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial
Lung Cancer 70/1 :77-81,2010

Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression
CANCER SCIENCE 101/10 :2200-2206,2010

The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 136/ :517-526,2010

Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA)-guided versus Empirical Chemotherapy in Unresectable Non-small Cell Lung Cancer
Anticancer Research 29/10 :4243-4249,2009

Prognosis of pN3 stage gastric cancer
Cancer Research And Treatment 41/2 :73-79,2009

크론병과 연관된 복강 내 농양에서 비수술 치료의 효용성
Korean Journal Of Gastroenterology 53/1 :29-35,2009

한국 성인 알레르기 비염 환자의 삶의 질 평가를 위한 설문지 개발 및 유용성 평가를 위한 연구
천식 및 알레르기 28/2 :113-120,2008